Crescent Biopharma, Inc. Working Capital to Net Assets Ratio
Crescent Biopharma, Inc. working capital to net assets ratio. Crescent Biopharma, Inc. (CBIO) has a Working Capital to Net Assets ratio of 98.3% as of June 2026. Working capital of $160.47 Million (current assets of $179.01 Million minus current liabilities of $18.54 Million) is measured against net assets of $163.25 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check CBIO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Crescent Biopharma, Inc. (2011–2025)
Working capital to net assets ratio of Crescent Biopharma, Inc. from 2011 to 2025. This chart shows how Crescent Biopharma, Inc.'s Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 98.3%, reflecting working capital of $160.47 Million against net assets of $163.25 Million USD. See CBIO days of operational coverage to measure how many days the company can operate on defensive assets alone.
Crescent Biopharma, Inc. Working Capital to Net Assets Ratio by Year (2011–2025)
Crescent Biopharma, Inc. working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Crescent Biopharma, Inc. from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Crescent Biopharma, Inc. balance sheet assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 98.8% | $200.58 Million | $203.01 Million | $236.66 Million | $36.07 Million | ▲ +261.5 pp |
| 2024 | -162.7% | $25.19 Million | $-15.48 Million | $34.80 Million | $9.61 Million | ▼ -258.9 pp |
| 2023 | 96.2% | $36.96 Million | $38.41 Million | $43.79 Million | $6.84 Million | ▼ -1.2 pp |
| 2022 | 97.4% | $41.83 Million | $42.93 Million | $50.71 Million | $8.88 Million | ▲ +0.7 pp |
| 2021 | 96.8% | $78.96 Million | $81.60 Million | $90.79 Million | $11.82 Million | ▼ -1.4 pp |
| 2020 | 98.1% | $125.84 Million | $128.22 Million | $138.27 Million | $12.43 Million | ▼ -0.2 pp |
| 2019 | 98.3% | $151.58 Million | $154.20 Million | $162.53 Million | $10.95 Million | ▼ -0.7 pp |
| 2018 | 99.0% | $203.51 Million | $205.46 Million | $212.27 Million | $8.76 Million | ▼ -0.4 pp |
| 2017 | 99.5% | $119.04 Million | $119.70 Million | $127.22 Million | $8.17 Million | ▲ +2.6 pp |
| 2016 | 96.8% | $34.19 Million | $35.30 Million | $40.52 Million | $6.33 Million | ▼ -0.7 pp |
| 2015 | 97.6% | $39.50 Million | $40.47 Million | $47.24 Million | $7.75 Million | ▼ -0.1 pp |
| 2014 | 97.7% | $49.65 Million | $50.80 Million | $56.12 Million | $6.46 Million | ▲ +8.2 pp |
| 2013 | 89.6% | $2.60 Million | $2.91 Million | $4.88 Million | $2.28 Million | ▼ -8.4 pp |
| 2012 | 98.0% | $12.28 Million | $12.53 Million | $17.97 Million | $5.69 Million | ▼ -43.4 pp |
| 2011 | 141.4% | $11.95 Million | $8.46 Million | $28.37 Million | $16.41 Million | — |